Abstract library

738 results for "under".
#1342 To Evaluate Patient’s Understand of the Neuroendocrine (NET) Multidisciplinary Team (MDT) Meeting Process at a ENETs Centre of Excellence
Introduction: Multidisciplinary teams serve to streamline the patient journey by developing individual treatment plans that are based on ‘best practice'. National and local guidelines govern the MDT process. There is little focus on the patient’s understanding and expectations of how and when the MDT recommendations are communicated.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: Miss Christina Rigby
Authors: Rigby C
Keywords: Patient MDT
#1263 Pretherapy Identification of Patients at Risk of Receiving a High Renal Dose Undergoing Peptide Receptor Radionuclide Therapy
Introduction: 68GaDOTA TATE imaging of patients with neuroendocrine tumours has shown that tumour sequestration is a major factor leading to a sink effect that decreases activity concentration in healthy tissues, particularly the renal parenchyma.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Steven Goodman
Keywords: dosimetry, PRRT
#2798 Risk of Pre-Operative Understaging of Duodenal Neuroendocrine Tumors at Conventional Imaging: When Surgery Becomes the First Choice
Introduction: Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors that can exhibit aggressive behavior, with loco-regional nodes and distant metastases. Pre-treatment staging is the basis for planning either surgical or endoscopic treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: dr Sara Massironi
#307 Prognostic Features in Patients with Metastatic Neuroendocrine Tumor Undergoing Y-90 Embolization
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms originating from enterochromaffin cells. NET patients with liver metastases frequently undergo Yttrium-90 (Y90) embolization.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Michelle Kim
#1305 PRRT for Malignant Pheochromocytomas and Paragangliomas: The Singapore General Hospital Experience
Introduction: In recent years, the use of 177Lu-DOTATATE radioisotope therapy has been expanded to patients with metastatic pheochromocytomas and paragangliomas (PCC/PGL). Although this is not the standard of care, treatment options are limited for those with MIBG negative disease. Our centre has treated over 40 patients with NETS with PRRT since 2012.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Lih Ming Loh
#1661 Investigating the Increasing Incidence of Neuroendocrine Tumors in Pakistan as a Result of Increased Awareness
Introduction: Incidence of Neuroendocrine tumors has been increasing worldwide. The reasons for this rising incidence remains unknown.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#1889 FNA Under Percutaneous Ultrasound or Endoscopic Ultrasound for Pre-Operative Diagnosis and Grading Determination in PanNET. Are They Reliable to Define a Tailored Therapy?
Introduction: Fine-needle aspiration cytology (FNA)under percutaneous ultrasound guided (pUS)or endoscopic ultrasound(EUS)control is a minimally invasive technique allowing diagnosis and grading determination in pancreatic neuroendocrine tumors (PanNET).Obtaining a correct cytological diagnosis is crucial for a tailored therapy
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: MD Roberta Rota
Keywords: FNA, Ki67
#2278 Incidental Histological Diagnosis of Small Pancreatic Neuroendocrine Tumors: Are We Underestimating Their Incidence?
Introduction: The annual incidence of pancreatic neuroendocrine tumours (PanNET) has been estimated to be around 0.8/100,000 inhabitants.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. Fabio Giannone
#616 Assessment of DNA Double-Strand Breaks in Blood Lymphocytes after Whole-Body Radiation Exposure in Patients with Neuroendocrine Tumors Undergoing 177Lu-Octreotate Therapy
Introduction: Peptide receptor radionuclide therapy using somatostatin receptor-binding peptides, such as 177Lu-Octreotate (LuTate), has been clinically proven to be effective in treating patients with inoperable neuroendocrine tumors. Despite the rather high radiation exposure, only few side effects have been reported. However, blood cells are very sensitive to radiation. Therefore, it is important to determine how much radiation they received. Recently, the detection by immunofluorescence of the phosphorylation of the histone variant H2AX (γ‐H2AX) has been established as a reliable and sensitive technique to monitor DNA double-strand breaks (DSBs) in blood lymphocytes.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Delphine Denoyer
#1735 Follow-Up in Neuroendocrine Neoplasms: Can Chromogranin A Be the Cofounder?
Introduction: Chromogranin A continues to be one of the most valuable markers for neuroendocrine tumors (NETs) however, it has several limitations.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Dr Diana Martins